DANDRIT BIOTECH USA, INC. (OTCBB:DDRT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

On December 6, 2016, DanDrit Biotech USA, Inc., a Delaware
corporation (the Company), held a special meeting of
stockholders (the Meeting) as prescribed in the Proxy
Statement filed by the Company with the SEC on November 21, 2016.
At the Meeting, as described under Item 5.07 below, the
stockholders of the Company approved an amendment to the Companys
Certificate of Incorporation to change the name of the Company
from DanDrit Biotech USA, Inc., to OncoSynergy, Inc., and to
effect a 1-for-2.3 reverse stock split, which amendment will
become effective upon the filing of a Certificate of Amendment
(Amendment) with the Secretary of State of Delaware.

The Amendment is attached as Annex A to the Proxy Statement and
is incorporated by reference herein.

Item 5.07.Submission of Matters to a Vote of Security
Holders.

At the Meeting, a total of 7,768,394 shares of the Companys
common stock, par value $0.0001 per share (Common Stock),
were present or represented by proxy, representing approximately
eighty one percent (81%) of the outstanding Common Stock as of
October 31, 2016, the record date for the Meeting.

At the Meeting, five (5) proposals were submitted for a vote of
the Companys stockholders and the related results are as follows:

Proposal No. 1: The election of Dr. Eric Leire, N.E.
Nielsen, and Aldo Petersen for terms until the next annual
meeting of stockholders or until such directors successor shall
have been duly elected and qualified. The stockholders elected
the three (3) directors with the following votes:

Proposal No. 2: A proposal to amend the Companys
Certificate of Incorporation to change the name of the Company
from DanDrit Biotech USA, Inc. to OncoSynergy, Inc. was passed
with the following votes:

Proposal No. 3: A proposal to amend the Companys Charter
to effect a 1-for-2.3 reverse stock split, which ratio may be
changed at the discretion of the Companys board of directors, of
the Companys issued and outstanding shares of Common Stock,
effective upon a date to be determined by the Companys board of
directors, was passed with the following votes:

Proposal No. 4: The stockholders ratified Gregory
Associates, LLC as the Companys independent registered accounting
firm by the following votes:

Proposal No. 5: A proposal to adjourn the special meeting,
if necessary or appropriate, to solicit additional votes and
proxies if there are insufficient votes at the time of the
Meeting or to approve the foregoing proposals passed with the
following votes:

About DANDRIT BIOTECH USA, INC. (OTCBB:DDRT)

DanDrit Biotech USA, Inc. is a biotechnology company. The Company focuses on developing vaccine against colorectal cancer. The Company has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The Company offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. As of June 30, 2016, the Company’s platform technology consists of two arms: autologous dendritic cells obtained by the activation of patient-derived monocytes, and lysate from melanoma-derived cell line expressing a range of cancer/testis antigens, including the melanoma-associated antigen (MAGE)-A family.

DANDRIT BIOTECH USA, INC. (OTCBB:DDRT) Recent Trading Information

DANDRIT BIOTECH USA, INC. (OTCBB:DDRT) closed its last trading session down -0.30 at 1.40 with 5,900 shares trading hands.